From GlobeNewswire: 2025-03-13 07:30:00

Tourmaline Bio, Inc. announces financial results for Q4 and year ending December 31, 2024. They reported $294.9 million in cash, cash equivalents, and investments, with an expected cash runway into the second half of 2027. The Phase 2 TRANQUILITY trial for pacibekitug is over-enrolled with 143 participants, on track for topline data in Q2 2025.

Tourmaline strengthens its Cardiovascular Scientific Advisory Board with recent appointments of Drs. Bhatt, Gill, Ridker, and Simon. These additions bring valuable expertise to guide the development of pacibekitug for cardiovascular diseases. The company’s strong balance sheet and expert team position them for clinical data readouts and progress in 2025.

In 2024, Tourmaline executed key clinical development programs for cardiovascular inflammation and thyroid eye disease, positioning them for transformative data readouts in 2025. The Phase 2 TRANQUILITY trial over-enrolled to 143 participants, advancing pacibekitug towards potential treatment for atherosclerotic cardiovascular disease. Further trials are planned for additional indications post-TRANQUILITY results.

Tourmaline’s Phase 2b spiriTED trial for thyroid eye disease continues, with topline data expected in the second half of 2025. The company plans to expand its development in TED based on the outcomes of the spiriTED trial. The bolstered Cardiovascular Scientific Advisory Board provides strategic guidance for pacibekitug development in reducing cardiovascular inflammation.

Financially, Tourmaline reported $20.5 million in research and development expenses for Q4 2024, with a total of $67.0 million for the year. General and administrative expenses were $5.3 million for Q4 and $22.7 million for the year. The net loss was $22.2 million for Q4 and $73.2 million for the year, with a strong cash position for future operations.

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for immune and inflammatory diseases. Their lead asset, pacibekitug, shows promise in treating cardiovascular inflammation and thyroid eye disease. For more information, visit their website or follow them on LinkedIn for updates on their innovative developments.



Read more at GlobeNewswire:: Tourmaline Bio Reports Fourth Quarter and Full Year 2024